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Abstract
Background
Aiming to contribute to prevention of cardiovascular disease (CVD), the National Health Ser-
vice (NHS) Health Check programme has been implemented across England since 2009.
The programme involves cardiovascular risk stratification—at 5-year intervals—of all adults
between the ages of 40 and 74 years, excluding any with preexisting vascular conditions
(including CVD, diabetes mellitus, and hypertension, among others), and offers treatment to
those at high risk. However, the cost-effectiveness and equity of population CVD screening
is contested. This study aimed to determine whether the NHS Health Check programme is
cost-effective and equitable in a city with high levels of deprivation and CVD.
Methods and findings
IMPACTNCD is a dynamic stochastic microsimulation policy model, calibrated to Liverpool
demographics, risk factor exposure, and CVD epidemiology. Using local and national data,
as well as drawing on health and social care disease costs and health-state utilities, we
modelled 5 scenarios from 2017 to 2040:
1. Scenario (A): continuing current implementation of NHS Health Check;
2. Scenario (B): implementation ‘targeted’ toward areas in the most deprived quintile with
increased coverage and uptake;
3. Scenario (C): ‘optimal’ implementation assuming optimal coverage, uptake, treatment, and
lifestyle change;
4. Scenario (D): scenario A combined with structural population-wide interventions targeting
unhealthy diet and smoking;
5. Scenario (E): scenario B combined with the structural interventions as above.
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We compared all scenarios with a counterfactual of no-NHS Health Check.
Compared with no-NHS Health Check, the model estimated cumulative incremental
cost-effectiveness ratio (ICER) (discounted £/quality-adjusted life year [QALY]) to be
11,000 (95% uncertainty interval [UI] −270,000 to 320,000) for scenario A, 1,500 (−91,000
to 100,000) for scenario B, −2,400 (−6,500 to 5,700) for scenario C, −5,100 (−7,400 to
−3,200) for scenario D, and −5,000 (−7,400 to −3,100) for scenario E. Overall, scenario A is
unlikely to become cost-effective or equitable, and scenario B is likely to become cost-effec-
tive by 2040 and equitable by 2039. Scenario C is likely to become cost-effective by 2030
and cost-saving by 2040. Scenarios D and E are likely to be cost-saving by 2021 and 2023,
respectively, and equitable by 2025. The main limitation of the analysis is that we explicitly
modelled CVD and diabetes mellitus only.
Conclusions
According to our analysis of the situation in Liverpool, current NHS Health Check implemen-
tation appears neither equitable nor cost-effective. Optimal implementation is likely to be
cost-saving but not equitable, while targeted implementation is likely to be both. Adding
structural policies targeting cardiovascular risk factors could substantially improve equity
and generate cost savings.
Author summary
Why was this study done?
• Previous evidence for population cardiovascular screening (e.g., National Health Service
[NHS] Health Check in England) has failed to conclusively provide answers around
effectiveness, cost-effectiveness, and equity.
• A recent systematic review found some evidence of cost-effectiveness, but some of the
studies included were methodologically flawed.
What did the researchers do and find?
• The researchers simulated the life courses of synthetic individuals under different sce-
narios, within a close-to-reality synthetic population of Liverpool.
• This study provides detailed evidence on effectiveness, cost-effectiveness, and equity of
health checks while also uniquely providing estimations of the speed at which these pro-
grammes will reach these thresholds.
• The results show that, while different implementation structures for health checks may
improve cost-effectiveness and equity, these approaches are dominated by the addition
of population-wide, structural interventions to improve diet and reduce smoking (e.g.,
mandatory salt reformulation of processed foods or increased taxation on tobacco
products).
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• Liverpool is a city with a high concentration of cardiovascular risk factors and high bur-
den of cardiovascular disease (CVD), and therefore the likelihood of programme effec-
tiveness increases.
What do these findings mean?
• The findings highlight the importance of a carefully considered approach to the imple-
mentation of health checks while also considering other approaches for CVD
prevention.
• The addition of structural interventions will lead to primary CVD prevention becoming
equitable and cost-effective earlier.
Introduction
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality globally [1]. In
2015, almost 500,000 deaths across the United Kingdom were attributed to CVD, more than
any other cause of death [2]. As part of the prevention of CVD, the National Health Service
(NHS) Health Check programme was implemented across England in 2009. Local-authority
commissioning of NHS Health Check has been a statutory requirement since 2013 as part of
the Health and Social Care Act [3]. The programme involves CVD risk stratification—at
5-year intervals—of all adults between the ages of 40 and 74 years, excluding any with known
preexisting vascular conditions (including CVD, diabetes mellitus, and hypertension, among
others) [4]. Those identified as high-risk are offered appropriate treatment, including pharma-
cological and behavioural interventions. There are limited data available on the national pro-
gramme. There is little consistency in commissioning arrangements; however, most areas use
local General Practices (GPs).
There is conflicting evidence regarding the effectiveness—and cost-effectiveness—of health
checks. In the UK, cost-effectiveness for public health interventions is often compared to a
threshold of £20,000 per quality-adjusted life year (QALY) gained [5]. The programme was
modelled by the UK Department of Health in 2008 [6], suggesting that health checks were
cost-effective. However, concern was raised that assumptions about the effectiveness of life-
style interventions might have been overestimated. A more recent study looking only at the
weight-loss impact of NHS Health Check found them cost-effective, through attributing the
weight-loss effect exclusively to health checks [7]. A Cochrane review found that, while health
check programmes increased diagnosis, they had no significant effect on survival; however, the
majority of studies in the review were from before 1980, prior to the introduction of many
pharmacological interventions (such as statins for hypercholesterolaemia) [8]. A systematic
review of economic evaluations for health checks reported that some modelling and obser-
vational studies found programmes to be cost-effective. However, some of these were me-
thodologically flawed (i.e., pre–post designs without a control group) and were based on
assumptions regarding uptake and treatment effectiveness that are not supported by empirical
evidence [9]. A recent study has suggested that targeting health checks to those most at risk
might increase cost-effectiveness [10].
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There are also concerns about the potential effect of health checks on health inequalities.
An analysis of the first 4 years of the NHS Health Check programme suggested low, but
improving, overall uptake and higher uptake in the most deprived communities. However,
this did not incorporate a complete 5-year cycle; therefore, it may reflect that, in some areas,
the invitation strategy prioritised people with lower socioeconomic circumstances [11]. A
rapid systematic review for the Expert Scientific and Clinical Advisory Panel identified that
there was wide variability in uptake across England, and the evidence regarding differential
uptake by sex, ethnicity, or deprivation was inconclusive [12]. Public Health England (PHE)
recently suggested that the programme could potentially be successful in reducing inequalities,
but this would require high and equitable uptake in high-risk groups [13]. Local authorities
have the flexibility to focus more resources on high-risk communities, making a targeted
approach on top of universal coverage possible through an approach of proportionate uni-
versalism [14]. A microsimulation study suggests that this could increase the equity of the
intervention [15]. Yet there is continuing concern that interventions that target high-risk indi-
viduals such as the Health Check programme might exacerbate health inequalities given that
they have the potential to favour populations with higher levels of resources [16,17].
On the other hand, population-wide policy approaches to reducing CVD can be effective,
cost-effective, and improve health inequalities [16]. These approaches typically focus on
tobacco and alcohol control as well as dietary interventions, such as mandatory salt reformula-
tion of processed food or a sugar-sweetened beverage (SSB) levy [18–23]. Therefore, the opti-
mal combination of individual and population-level strategies to reduce the unequal burden of
CVD is still not well-defined.
The current study focusses on Liverpool, a city in northwest England with high levels of
socioeconomic deprivation. Liverpool is ranked the fourth most deprived local authority in
England when considering the proportion of neighbourhoods in the most deprived quintile
[24]. Furthermore, there are high levels of inequality within the city, with notable clustering of
CVD risk factors that might favour targeted, high-risk approaches to prevention. Health
checks were implemented in Liverpool in 2010, but this remains suboptimal; an audit of the
programme in 2015 and 2016 found large variations in practice [25]. Barely two-thirds of eligi-
ble residents were invited, of which less than one-third completed a health check. These figures
are below the national average of about 86% and 49%, respectively [26]. Patients from more
deprived areas were significantly less likely to attend, and men less so than women.
The aim of this study was therefore to quantify the cost-effectiveness and equity impact of
the NHS Health Check programme in Liverpool, comparing current implementation, targeted
implementation, or their combination with structural interventions.
Methods
The IMPACTNCD model, a discrete-time stochastic microsimulation, was used to counterfac-
tually simulate individual life courses in the scenarios. The model structure and validation is
described in detail elsewhere [20,27,28]. We present, in detail, model inputs, model outputs,
scenario specification, and additional results and validation in S1 Text. In brief, we set the sim-
ulation horizon to 2040 to enable this preventative intervention to have time to become effec-
tive, and we present the results for ages 30 to 84.
Model inputs
We inputted data on demographics and projections (by age, sex, and English Index of Multiple
Deprivation quintile group [QIMD]) for Liverpool into the IMPACTNCD model to create a
synthetic dynamic population of 200 million adults aged 30 to 84 at baseline. QIMD is a
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measure of relative area deprivation based on the Index of Multiple Deprivation [29].
According to this system, all Lower Super Output Areas in England (average population of
1,500) are ranked in order of increasing deprivation, based on 7 domains of deprivation:
income; employment; health deprivation and disability; education, skills, and training; bar-
riers to housing and services; crime and disorder; and living environment. Then, the QIMD
is formed from the quintiles of the above index. Population exposure to 7 known CVD risks
was extracted from the Health Survey for England (HSE) using a subsample of northwest
England residents. The 7 risks were inadequate fruit and vegetable consumption, physical
inactivity, smoking, high body mass index, hypertension, hypercholesterolaemia, and diabe-
tes mellitus. Trends in these risks between 2002 and 2014 were projected to 2040, stratified
by demographics, to estimate future exposure. We used the published relative risks from
high-quality meta-analyses and cohort studies to link risk factor exposure with disease out-
comes. Table 1 summarises the input sources for IMPACTNCD, and Table 2 presents the key
modelling assumptions.
Model outputs
The following list summarises model outputs:
1. CVD cases and deaths prevented or postponed by a modelled intervention, cumulatively
over the simulated years.
2. Non-CVD deaths prevented or postponed by a modelled intervention, cumulatively over
the simulated years. The model only considers smoking- and diabetes-related prevented or
postponed non-CVD deaths.
3. QALYs gained because of a modelled intervention, cumulatively over the simulated years.
4. The net cost of a modelled intervention, cumulatively over the simulated years.
5. The incremental cost-effectiveness ratio (ICER) of a modelled intervention, as the ratio of
cumulative net cost by cumulative QALYs gained (cost–utility analysis).
6. The net monetary benefit (NMB) assuming £20,000 willingness to pay.
7. The impact of an intervention on absolute and relative socioeconomic inequalities in
health. We used the ‘absolute equity slope index’ and ‘relative equity slope index’—2 regres-
sion-based metrics—to measure the impact of the modelled interventions on absolute and
relative socioeconomic health inequalities [27].
Uncertainty and sensitivity analysis
Second-order Monte Carlo simulation was used to estimate 95% uncertainty intervals (UIs),
propagating estimated uncertainty of inputs to the outputs. Many sources of uncertainty are
shared between scenarios; therefore, between-scenario results are not statistically independent
and covary to an extent. Therefore, a crossover between UIs for scenarios should not be seen
as evidence against statistical significance (please refer to S1 Text for between-scenario com-
parisons). We present the probability estimates of each scenario being cost-effective (net cost
of less than £20,000 per QALY gained), cost-saving (negative net cost), and equitable (reduces
both absolute and relative socioeconomic inequalities in health). We defined a probability
threshold of 80% to determine when—or whether—a scenario becomes cost-effective (or cost-
saving, or equitable).
Health Check CEA in Liverpool
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Table 1. IMPACTNCD data sources.
Parameter Outcome Details Comments Source
Mortality rates Deaths from
nonmodelled causes
Mortality and midyear population
estimates for England
Stratified by age, sex, QIMD, and cause of death.
Years 2002–2013.
Data requested and obtained
by the Office for National
Statistics [30]
Population
projections for
Liverpool
Population size Midyear population figures for
Liverpool
Stratified by age and sex. Years 2014–2039.
QIMD distribution was assumed to remain stable
as in 2011. Population size for year 2040 was
assumed the same as 2039.
Subnational population
projections [31]
Exposure to risk
factors
Exposure of
individuals
HSE (northwest subsample) Anonymised, individual-level datasets. Years
2001–2012.
HSE 2002–2014 [32–44]
RR for active
smoking
CHD and stroke
(ICD10: I20–I25 and
I60–I69)
Re-analysis of American Cancer
Society’s Cancer Prevention Study
II. Prospective cohort study, 6 years
of follow-up
Stratified by age and sex. Adjusted for age, race,
education, marital status, ‘blue collar’
employment in most recent or current job,
weekly consumption of vegetables and citrus
fruit, vitamin (A, C, and E) use, alcohol use,
aspirin use, body mass index, exercise, dietary fat
consumption, hypertension, and diabetes at
baseline.
Table 1 (Model B) in Ezzati
and colleagues [45]
Other mortality
(except CHD and
stroke)
Male British doctors prospective
cohort study
Age-standardised Table 1 in Doll and colleagues
[46]
RR for ex-smoking CHD (ICD10: I20–
I25)
Meta-analysis. Multiple-adjusted
pooled estimates from 19
prospective studies
Multiply-adjusted Web Figure 8 in Huxley RR
and colleagues [47]
Stroke (ICD10 I60–
I69)
The Framingham study. Prospective
cohort study
Stroke risk decreased significantly by 2 years and
was at the level of nonsmokers by 5 years after
cessation of cigarette smoking. Therefore, we
considered no risk for ex-smokers.
Wolf and colleagues [48]
RR for
environmental
tobacco smoking
CHD (ICD10: I20–
I25)
Meta-analysis of 10 cohort and case-
control studies
Adjusted for important CHD risk factors. Table 3 (adjusted RR) in He
and colleagues [49]
Stroke (ICD10 I60–
I69)
Meta-analysis of 20 prospective,
case-control, and cross-sectional
studies
Thirteen studies adjusted for important CHD risk
factors. The overall effect of all 20 studies was
used.
Figure 1 in Oono and
colleagues [50]
RR for systolic blood
pressure
CHD and stroke
(ICD10: I20–I25 and
I60–I69)
Meta-analysis of individual data
from 61 prospective studies
Stratified by age and sex. Adjusted for regression
dilution and total blood cholesterol and, where
available, lipid fractions (HDL and non-HDL
cholesterol), diabetes, weight, alcohol
consumption, and smoking at baseline.
Figures 3 and 5 in Prospective
Studies Collaboration [51]
RR for total
cholesterol
CHD and stroke
(ICD10: I20–I25 and
I60–I69)
Meta-analysis of individual data
from 61 prospective studies
Stratified by age and sex. Adjusted for regression
dilution and age, sex, study, systolic blood
pressure, and smoking.
Web Table 6 (fully adjusted)
and Figure 3 in Prospective
Studies Collaboration [52]
RR for body mass
index
CHD and stroke
(ICD10: I20–I25 and
I60–I69)
Meta-analysis of 58 prospective
studies
Stratified by age. Adjusted for age, sex, smoking
status, systolic blood pressure, history of diabetes,
and total and HDL cholesterol. We used the age
gradient from the adjusted only for age, sex, and
smoking status reported estimates.
Table 1 and Figure 2 in The
Emerging Risk Factors
Collaboration [53]
RR for diabetes
mellitus
CHD and stroke
(ICD10: I20–I25 and
I60–I69)
Meta-analysis of 102 prospective
studies
Stratified by age. Adjusted for age, smoking
status, body mass index, and systolic blood
pressure.
Figure 2 in The Emerging
Risk Factors Collaboration
[54]
Other mortality
(except CHD and
stroke)
DECODE. A collaborative
prospective study of 22 cohorts in
Europe
Adjusted for body mass index, blood pressure,
smoking, and serum cholesterol.
The DECODE Study Group
[55]
RR for physical
activity
CHD and stroke
(ICD10: I20–I25 and
I60–I69)
Meta-analysis of 18 cohort studies
for CHD and 8 cohort studies for
ischaemic stroke
Stratified by age and sex. Adjusted for
measurement error, age, sex, smoking, blood
pressure, and cholesterol.
Tables 10.19 and 10.20 in Bull
and colleagues [56]
(Continued)
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Costs
We used local audit data to determine costs [25], while anonymised aggregated data from the
local Clinical Commissioning Group were used to estimate prescription rates. The modelled
costs were based on the payment that Liverpool City Council makes to GPs to provide the
NHS Health Check programme [25]. This is £5.11 for an invitation and £13 to £19 per partici-
pant who undergoes a Health Check. The range of participation cost reflects that Liverpool
City Council incentivises GP practices that achieve high uptake. Disease costs were drawn
from NICE economic modelling and were separated by the first year of diagnosis, subsequent
years, and fatal CVD events [60–63]. Deprivation weighting was used to match the deprivation
profile of Liverpool, as there is evidence that there is a social gradient of costs [64]. Estimates
assume that costs are equal for all ages and sexes, while myocardial infarction is used as a
proxy for coronary heart disease (CHD). Non-CVD complications of diabetes are not
included in cost estimates. Costs are inflated using the UK Treasury GDP deflator, November
2016 [65].
Table 1. (Continued)
Parameter Outcome Details Comments Source
RR for fruit and
vegetable
consumption
CHD (ICD10: I20–
I25)
Meta-analysis of 9 cohort studies RR per portion of F&V. Multiply-adjusted. Dauchet and colleagues [57]
Stroke (ICD10: I60–
I69)
Meta-analysis of 7 cohort studies RR per portion of F&V. Multiply-adjusted. Dauchet and colleagues [58]
Persistence with
medication
Persistence to statins
for primary
prevention
Danish cohort study No clear socioeconomic gradient was observed. Wallach-Kildemoes and
colleagues [59]
Adherence to
medication
Persistence to statins
for primary
prevention
Danish cohort study No clear socioeconomic gradient was observed. Wallach-Kildemoes and
colleagues [59]
Abbreviations: CHD, coronary heart disease; F&V, fruit and vegetable; HDL, high-density lipoprotein; HSE, Health Survey for England; RR, relative risk; QIMD, Index
of Multiple Deprivation quintile group.
https://doi.org/10.1371/journal.pmed.1002573.t001
Table 2. IMPACTNCD key assumptions and limitations.
Assumptions and limitations
Migration flows and social mobility were not considered in our estimates.
We assumed that the data sources that we used are genuinely representative of the Liverpool population.
We did not explicitly model alcohol consumption.
We assumed multiplicative risk effects for all risk factors and log-linear exposure–response relationship for the
continuous ones.
We explicitly modelled hypertension, diabetes, CHD, and stroke. We defined CVD as the sum of CHD and stroke
cases (deaths). We did not model other noncommunicable diseases that could potentially be affected by the
modelled interventions.
We assumed that the observed trends in exposures and CVD mortality will continue in the future.
We assumed that trends in CHD and stroke incidence are attributable only to the modelled risk factor exposure
trends.
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease.
https://doi.org/10.1371/journal.pmed.1002573.t002
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Health-related quality of life
We searched for disease utility index score multipliers that used the Euroqol 5-dimension
scale (EQ-5D), which is seen as the ‘gold standard’ for health technology assessment in the UK
and is recommended by NICE [66]. The evidence base was used to determine baseline utility
scores by age [67]. A multiplier of 0.778 was used for CHD [68], 0.629 for stroke [69], and
0.901 for diabetes [70]. Hypertension was not given a multiplier because there was no consis-
tent evidence, especially considering the link between hypertension and other morbidities.
Productivity losses
Productivity losses were estimated separately for CHD and stroke, accounting for both work-
ing years lost due to early mortality and sickness absence [71,72]. Prices were inflated using
ONS data, then weighted based on Liverpool median earnings (95% of the median earnings
for the UK). Indirect costs (such as informal care) were not included, and productivity losses
were not included in the main cost estimations, which were from a health and social care
perspective.
Discounting
An annual discount rate of 3.5% was applied from 2016 to net costs and QALYs. Results from
prior to 2016 were inversely discounted. This rate was selected based on guidance from the
UK Treasury [73].
Scenarios
In total, 20 scenarios were progressively developed through an iterative process with public
health practitioners in Liverpool. Those scenarios included isolated improvements in coverage,
uptake, prescription, referrals to lifestyle services, and some of their combinations. None were
shown to be substantially better than the current implementation except the 5 scenarios we
present in this study (for a detailed description and justification, please refer to S1 Text).
(A) Current implementation. In this scenario, we modelled the impact and costs assuming
that the NHS Health Check programme continued unchanged in Liverpool throughout the
modelled period to 2040. This assumed that annual coverage would remain at 13.8%, annual
uptake would be 32.3%, and prescription rates would be 9.1% for low-risk, 25.8% for medium-
risk, and 41.7% for high-risk participants. The costs were estimated at £5.11 per invitation and
£13.28 per successful participation in NHS Health Check.
(B) Current plus targeted. In this scenario depicting a proportionate universalism
approach, we modelled the impact and costs if the NHS Health Check programme was tar-
geted toward individuals in the most deprived quintile, with increased coverage and uptake in
this population while coverage and uptake in all other groups remain as the current implemen-
tation scenario. The coverage in the most deprived quintile is assumed to be 20%, with uptake
at 66%. Crucially, in this scenario, we assume that the hypothetical recruitment strategy in the
most deprived areas manages to attract participants with a higher cardiovascular risk profile
than in scenario A. Prescription rates are unchanged from the current implementation sce-
nario. The costs were estimated at £5.11 per invitation and £15.00 per successful participation
in NHS Health Check. The increase in participation cost is in line with current Liverpool City
Council practice to monetarily incentivise GP practices that achieve high uptake.
(C) Optimal uptake and prescription rates. In this scenario, we modelled the impact and
costs if the NHS Health Check programme met the PHE requirements to invite 20% of the eli-
gible population, and uptake was 66% [74]. Prescription rates in this scenario were set to 9.1%
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for low-risk, 80% for medium-risk, and 80% for high-risk participants to better reflect current
prescription guidelines. In addition, we assumed highly effective lifestyle services. The costs
were estimated at £5.11 per invitation and £15.00 per participant.
(D) Current plus structural interventions. This scenario modelled the impact and costs of
the current implementation of NHS Health Check (scenario A) with the addition of structural
interventions. The structural interventions were stricter tobacco control, an increase of fruit
and vegetable consumption by a portion per day in 50% of individuals in the population, man-
datory salt reformulation of processed foods, and an SSB tax of 20%. Their effectiveness was
informed by published, mostly modelling studies [20,21,75–77].
(E) Current plus targeted plus structural interventions. This scenario modelled the
impact and costs of the targeted implementation of NHS Health Check (scenario B) with the
addition of structural interventions. The structural interventions are as in the previous
scenario.
All results were reported following CHEERS guidelines (S1 CHEERS Checklist).
Results
The model estimated that about 94% (95% UI: 93% to 96%) of CHD incidence can be attrib-
uted to the modelled risk factors in the least-deprived quintile group. This gradually increased
with deprivation to reach 96% (95% UI: 94% to 97%) for the most-deprived quintile group.
Similarly, for stroke, the proportions were 86% (95% UI: 81% to 90%) and 92% (95% UI: 89%
to 94%) for the least- and most-deprived quintile groups, respectively.
Effectiveness
Table 3 compares scenarios considering the number of CVD cases prevented and number of
QALYs gained. The ‘current implementation’ was the worst-performing scenario for both out-
comes and by both years (2030 and 2040). The ‘optimal implementation’ of Health Check per-
formed better (estimated to prevent or postpone approximately 750 and 2,000 CVD cases by
Table 3. Comparison table of the effectiveness of the modelled scenarios. Ages 30 to 84. Parentheses contain 95%
UIs. Results are rounded to the first 2 significant digits.
Model output Scenario By the year 2030 By the year 2040
Cumulative CVD cases prevented or
postponed
Current (A) 290 (150 to 500) 570 (320 to 890)
Current plus targeted (B) 530 (270 to 930) 1,200 (730 to
1,900)
Optimal (C) 750 (400 to 1,300) 2,000 (1,400 to
2,900)
Current plus structural (D) 1,600 (1,000 to
2,300)
3,300 (2,400 to
4,200)
Current plus targeted plus
structural (E)
1,800 (1,100 to
2,700)
3,800 (2,900 to
5,000)
Cumulative net QALYs gained
(discounted)
Current (A) 57 (−130 to 310) 220 (−110 to 660)
Current plus targeted (B) 85 (−200 to 490) 500 (−82 to 1,300)
Optimal (C) 310 (−110 to 960) 1,700 (700 to
3,100)
Current plus structural (D) 2,400 (1,100 to
4,300)
7,000 (4,600 to
10,000)
Current plus targeted plus
structural (E)
2,400 (1,000 to
4,500)
7,200 (4,700 to
10,000)
Abbreviations: CVD, cardiovascular disease; QALY, quality-adjusted life year; UI, uncertainty interval.
https://doi.org/10.1371/journal.pmed.1002573.t003
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2030 and 2040, respectively). However, that performance was dwarfed when structural inter-
ventions were added. The ‘targeted Health Check plus structural interventions’ was the best-
performing scenario, estimated to prevent or postpone approximately 1,800 and 3,800 CVD
cases by 2030 and 2040, respectively. Notably, even ‘current implementation plus structural
interventions’ outperforms all programme-only scenarios.
Cost-effectiveness
Table 4 and Fig 1 show cost-effectiveness analysis. The current implementation was unlikely to
become cost-effective before 2040, while the targeted implementation would only pass the 80%
threshold by 2040. The optimal implementation would pass the threshold by 2032. Compara-
tively, the addition of structural interventions means that scenarios D and E might become
cost-effective by 2023, almost a decade earlier. Fig 2 shows that current and targeted imple-
mentations are unlikely to be cost-saving by 2040, while optimal implementation might reach
the threshold by 2040. The current implementation with structural interventions could reach
cost-saving fastest—by 2024—while targeted and structural approaches are likely to achieve
cost-saving by 2026.
Equity
Table 5 and Fig 3 display findings concerning health inequalities. All 3 programme-only sce-
narios showed a decrease in absolute inequality—modest for the current implementation and
substantial for the optimal implementation. When considering relative inequalities, only the
targeted implementation was associated with an improvement in equity, crossing the 80%
threshold by 2039. By contrast, the structural intervention scenarios both resulted in much
larger improvements in both absolute and relative inequalities. Both would cross the 80%
threshold before 2025.
Table 4. Comparison table of the cost-effectiveness of the modelled scenarios. Negative net costs are essentially savings. Ages 30 to 84. Parentheses contain 95% UIs.
Results are rounded to the first 2 significant digits.
Model output Scenario By the year 2030 By the year 2040
Cumulative net cost (discounted £million) Current (A) 4.0 (1.1 to 6.2) 3.4 (−1.5 to 6.9)
Current plus targeted (B) 4.7 (−0.1 to 7.9) 1.3 (−8.6 to 7.5)
Optimal (C) 3.9 (−2.8 to 8.2) −4.2 (−18.0 to 4.3)
Current plus structural (D) −13.0 (−28.0 to −3.7) −35.0 (−60.0 to −19.0)
Current plus targeted plus structural (E) −11.0 (−27.0 to −1.7) −35.0 (−63.0 to −18.0)
Cumulative ICER (discounted £/QALY) Current (A) 21,000 (−650,000 to 730,000) 11,000 (−270,000 to 320,000)
Current plus targeted (B) 14,000 (−450,000 to 540,000) 1,500 (−91,000 to 100,000)
Optimal (C) 9,700 (−170,000 to 190,000) −2,400 (−6,500 to 5,700)
Current plus structural (D) −5,200 (−8,400 to −2,600) −5,100 (−7,400 to −3,200)
Current plus targeted plus structural (E) −4,600 (−7,700 to −1,400) −5,000 (−7,400 to −3,100)
Cumulative NMB (discounted £million) Current (A) −3.0 (−8.3 to 5.0) 0.9 (−8.6 to 14.0)
Current plus targeted (B) −3.0 (−11.0 to 10.0) 8.8 (−8.6 to 34.0)
Optimal (C) 2.5 (−10.0 to 22.0) 38.0 (10.0 to 79.0)
Current plus structural (D) 62.0 (27.0 to 110.0) 180.0 (120.0 to 250.0)
Current plus targeted plus structural (E) 60.0 (23.0 to 110.0) 180.0 (120.0 to 270.0)
Abbreviation: ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit; QALY, quality-adjusted life year; UI, uncertainty interval.
https://doi.org/10.1371/journal.pmed.1002573.t004
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Fig 1. Annual probability of the modelled scenarios to be cost-effective. Willingness to pay £20,000 per QALY. QALY,
quality-adjusted life year.
https://doi.org/10.1371/journal.pmed.1002573.g001
Fig 2. Annual probability of the modelled scenarios to be cost-saving.
https://doi.org/10.1371/journal.pmed.1002573.g002
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Productivity
All 5 scenarios would produce productivity savings by 2040 (Table 6). These savings would be
largest for the targeted Health Check plus structural interventions (scenario E), with savings of
approximately £23 million above the current implementation. This was over 5 times greater
savings than for targeted implementation (scenario B) alone and 4 times greater than the sav-
ings increase for optimal implementation.
Table 5. Comparison table of the equity of the modelled scenarios. Positive values represent a reduction in inequalities and vice versa. Ages 30 to 84. Parentheses con-
tain 95% UIs. Results are rounded to the first 2 significant digits.
Model output Scenario By the year 2030 By the year 2040
Reduction in absolute socioeconomic health inequalities Current (A) 150 (−570 to 1,100) 600 (−660 to 2,300)
Current plus targeted (B) 410 (−1,000 to 2,600) 2,900 (−360 to 7,700)
Optimal (C) 1,300 (−340 to 3,900) 7,200 (3,100 to 13,000)
Current plus structural (D) 13,000 (5,800 to 22,000) 37,000 (24,000 to 52,000)
Current plus targeted plus structural (E) 13,000 (5,300 to 23,000) 38,000 (25,000 to 55,000)
Reduction in relative socioeconomic health inequalities Current (A) −24 (−230 to 130) −76 (−330 to 140)
Current plus targeted (B) 11 (−150 to 200) 120 (−110 to 400)
Optimal (C) −2.1 (−270 to 210) −50 (−440 to 270)
Current plus structural (D) 550 (160 to 1,100) 1,200 (630 to 1,900)
Current plus targeted plus structural (E) 550 (130 to 1,200) 1,300 (670 to 2,000)
Abbreviation: UI, uncertainty interval.
https://doi.org/10.1371/journal.pmed.1002573.t005
Fig 3. Annual probability of the modelled scenarios to be equitable. We defined equitable as reducing both absolute and
relative socioeconomic inequalities in health.
https://doi.org/10.1371/journal.pmed.1002573.g003
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Discussion
Our study suggests that simply continuing the current implementation of the Health Check
programme in Liverpool is unlikely to be cost-effective or equitable, even when modelled 2
decades into the future. If implementation of the programme met optimal PHE recommenda-
tions for uptake and prescribing [74], then cost-effectiveness might be achieved by 2030 and
cost-savings achieved by 2040 for the Liverpool population. However, it would not improve rel-
ative health inequalities. Conversely, a targeted approach towards the most deprived (those at
the highest risk) would likely improve equity by 2039 but only reach cost-effectiveness by 2040.
Moreover, our findings may have wider implications nationally and beyond. NHS Health
Check is an intervention that targets high-risk individuals. Theoretically, these interventions
are more effective when the risk is concentrated in some subgroups of the population [78].
Historically, Liverpool is a city with concentrated deprivation and concentrated CVD risk that
translates consistently to worse CVD burden and outcomes compared to the national average
[79]. Therefore, we expect the effectiveness and cost-effectiveness of NHS Health Check—even
considering optimal implementation—to be worse elsewhere than in Liverpool.
These findings add to the results of a systematic review by Lee and colleagues in 2017 [9].
Analysing the evidence for the cost-effectiveness of population-wide CVD screening, the
review found that there was a lack of robust evidence to support the implementation of such
screening. As a result, the authors recommended that further evidence is required to identify
the cost-effectiveness of such screening, and different delivery models should be examined,
such as targeted implementation or population-wide interventions. This modelling study
examines these issues directly and provides the evidence recommended.
The addition of structural interventions addressing smoking, diet, and an SSB tax provides
a stark contrast. These scenarios would almost certainly be cost-effective, cost-saving, and
equitable and reach these 80% thresholds much more quickly. This is unsurprising when
remembering Rose’s paradigm about sick individuals and sick populations [80].
The UK Department of Health estimated that the ICER for NHS Health Check would be
under £3,000 per QALY gained [6]. However, our findings suggest the ICER would be substan-
tially higher than this by 2030, regardless of implementation. Furthermore, substantial
improvements to the delivery and implementation of NHS Health Check would be required to
achieve an ICER under £3,000 per QALY gained by 2040. Our estimates are comparable to
those from Crossan and colleagues suggesting that optimal implementation would reduce
ICERs, perhaps to less than £10,000 (versus £23,000 or more for typical implementation) [10].
The different estimates of these studies are due to differences in the modelled NHS Health
Check implementation—and thus effectiveness—and wider differences in the modelling
Table 6. CHD, stroke, and CVD net productivity discounted cost by the year 2040 (30 years). Ages 30 to 64. Parentheses contain 95% UIs. Negative values represent
savings. Results are rounded to the first 2 significant digits.
Scenario CHD net productivity cost
(£million)
Stroke net productivity cost
(£million)
Total CVD net productivity cost
(£million)
Current (A) −2.0 (−4.1 to −0.84) −0.74 (−1.7 to −0.18) −2.7 (−5.5 to −1.2)
Current plus targeted (B) −5.2 (−10.0 to 2.6) −1.7 (−3.7 to −0.69) −6.8 (−14.0 to −3.6)
Optimal (C) −5.5 (−11.0 to −2.9) −2.6 (−4.9 to −1.2) −8.1 (−15.0 to −4.5)
Current plus structural (D) −13.0 (−20.0 to −8.0) −9.8 (−15.0 to −6.1) −22.0 (−34.0 to −15.0)
Current plus targeted plus structural
(E)
−15.0 (−25.0 to −9.7) −10.0 (−17.0 to −6.7) −26.0 (−41.0 to −17.0)
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; UI, uncertainty interval.
https://doi.org/10.1371/journal.pmed.1002573.t006
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assumptions overall (i.e., assumptions regarding the future burden of CVD or use of different
simulation horizons).
Public health implications
These results from our IMPACTNCD model may be of particular interest to local commission-
ers. Public health interventions have generally been found to be cost-saving [81], thus NHS
Health Check appears to represent a comparatively expensive approach to prevention [82].
However, the NHS Health Check programme is currently a statutory requirement for local
governments in England. Given this and the major pressures on local-authority budgets [83],
the need to improve the cost-effectiveness of prevention programmes with the addition of
cost-saving interventions is becoming increasingly clear.
The UK government introduced a sweetened drinks industry levy (SSB tax) in April 2018
[84]. However, other population strategies to reduce CVD could be added. Rather than wait
for further action at the national level, we would advocate that local governments take the ini-
tiative in implementing population health-improvement strategies. Liverpool did that in the
past. In 2004, the local government took the initiative to make Liverpool a smoke-free city.
This local initiative was instrumental in the passage of the relevant national law 2 years later
[85].
A number of cities across the United States, such as Boston and Oklahoma [86,87], have
engaged in collective approaches to encourage healthier diets and weight loss. New York City
implemented a number of approaches to improve fruit and vegetable consumption, particu-
larly among low-income individuals [88]. These approaches included financial support to
reduce cost barriers, incentives to improve access, support to improve supply and demand for
healthy food, improving food quality in different organisations (including schools and child-
care centres), and individual support programmes. This combined approach was associated
with small but significant improvements in fruit and vegetable consumption. The legal and
political feasibility of similar local public health policies for English cities is largely unexplored.
Moreover, devolution deals such as those in Liverpool and Manchester may give local govern-
ments additional power to implement more structural preventive policies.
Strengths and limitations
To our knowledge, IMPACTNCD is the first dynamic stochastic microsimulation model to esti-
mate cost-effectiveness and equity of the NHS Health Check programme at a city level. Focus-
ing on the city level allowed us to use real-world data on disease rates, costs, and programme
success that are not easily available at the national level. In addition, the choice of Liverpool—a
city in which the concentration of CVD risk theoretically would favour NHS Health Check—
allows the derivation of useful analogies for other areas.
There are, however, a number of limitations. First, health-related quality of life decrements
were assumed equal across all socioeconomic groups. However, when considering CVD, peo-
ple from lower socioeconomic backgrounds have significantly reduced quality of life compared
to higher socioeconomic backgrounds. This is likely to underestimate our cost-effectiveness
and equity estimates for scenarios B and E [89]. Second, the costs for NHS Health Check only
consider the prices paid by the Liverpool City Council. We have assumed that these costs are
consistent and have not considered the potential effects of saturation or diminishing returns.
The costs of medications for CHD, stroke, diabetes, and hypertension are included in the
broad healthcare unit cost estimates. Only the costs of statins for people with no other diseases
are not explicitly included, but these costs are small, at around £20 to £40 per patient per
annum. Furthermore, we did not include opportunity costs, resulting in the potential for the
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Health Check to displace more effective health interventions [90]. Third, while most of the
structural policies we modelled are incremental improvements on existing policies, their politi-
cal feasibility is unclear in the current environment. Fourth, our model only considers CVD
and diabetes mellitus. Both NHS Health Check and the structural interventions we modelled
can potentially reduce the burden of other noncommunicable diseases, too.
Conclusions
Our results suggest that current NHS Health Check implementation appears neither equitable
nor cost-effective for local authorities. Optimal administration and implementation might
result in better value for money in the next few decades. However, the addition of structural
interventions could substantially reduce CVD risks, improve equity, and generate cost savings
within short time-scales.
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